stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
50.96
2.50
+5.16%
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) Net income
MBX Biosciences, Inc.'s net income for fiscal 2025 was −$87.0M, compared with −$61.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$104.3M. Net income has fallen for 3 consecutive fiscal years. MBX Biosciences, Inc. ranks 430th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$87.0M | — |
| FY2024 | −$61.9M | — |
| FY2023 | −$32.6M | — |
| FY2022 | −$26.1M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$37.1M | — |
| Mar 2026 | −$23.5M | — |
| Dec 2025 | −$22.1M | — |
| Sep 2025 | −$21.6M | — |
| 9 more quarters | Free account |
Net income against peers
| Company | Net income |
|---|---|
| ADMA ADMA Biologics Inc compare | $182.4M |
| MBX MBX Biosciences, Inc. | −$104.3M |
| XNCR Xencor, Inc. compare | −$163.3M |
| PHVS Pharvaris N.V. compare | −$193.1M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$198.4M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$204.9M |
| CLDX Celldex Therapeutics, Inc. compare | −$300.5M |
| RCUS Arcus Biosciences, Inc. compare | −$453.0M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$475.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item